Wan Han Li Liang: Focus on the research and development of innovative drugs, and strive to develop new biomedical products to meet market demand and patients' expectations. The company has patented technology or unique R&D platform in the biomedical field, providing technical support for the production of R&D and its products. Wanhan Li Liang focuses on specific market segments, such as rare disease drugs or personalized treatment, thus establishing market advantages in specific fields.
Nuotai Bio: focuses on the research and development of polypeptide drugs and small molecules, and has a rich product line, such as liraglutide, smeaglutide and so on. Thanks to the rapid growth of the global peptide bulk drug market, the company has broad prospects in the domestic market and is expected to benefit from the expansion of the industry. In addition to the research and development of existing products, Novotel also actively reserves oligonucleotides and small molecular platform research and development, laying the foundation for future growth.